RedHill Biopharma Ltd. (RDHL)
After hours:
| Previous close | 0.4545 |
| Open | 0.4565 |
| Bid | 0.3237 x 200 |
| Ask | 0.5798 x 200 |
| Day's range | 0.4413 - 0.4600 |
| 52-week range | 0.2570 - 3.2800 |
| Volume | |
| Avg. volume | 448,385 |
| Market cap | 14.499M |
| Beta (5Y monthly) | 3.45 |
| PE ratio (TTM) | 0.11 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).
- PR Newswire
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
- PR Newswire
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.
